AGEX THERAPEUTICS INC. (as Borrower) - and - JUVENESCENCE LIMITED (as Lender) - and – RECYTE THERAPEUTICS INC. (as Guarantor) - and – REVERSE BIOENGINEERING, INC. (as Guarantor) SECURED CONVERTIBLE FACILITY AGREEMENTConvertible Facility Agreement • March 30th, 2020 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • England and Wales
This Agreement shall set forth the terms and conditions upon which the Lender has agreed to provide a secured convertible facility to the Borrower, not exceeding the aggregate principal amount of up to US$8,000,000 (eight million dollars) on the terms and conditions set out in this Agreement.
Warrant AgreementWarrant Agreement • March 30th, 2020 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
WARRANT AGREEMENT, (this “Agreement”) dated as of March 30, 2020, by AgeX Therapeutics, Inc., a Delaware corporation (the “Company”), for the benefit of Juvenescence Limited which, along with any permitted successor Holder of a Warrant is referred to herein as a “Lender”.
AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 30th, 2020 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • California
This Amendment No. 1, dated as of March 30, 2020 (the “Amendment”), is entered into by and between AgeX Therapeutics, Inc., a California corporation (the “Company”) and Juvenescence Limited, a company incorporated in the British Virgin Islands (“Holder”). Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings ascribed thereto in the “Registration Rights Agreement” (as defined below) as amended hereby.
